Our Story
Lucy Biotech provides cutting-edge technologies for cryopreserving cells, tissues, and organs. Our solutions are inspired by nature and it is effective and non-toxic. Founded by a group of Canadian scientists who were fascinated by arctic species, today we offer an innovative approach to combat current challenges in cryobiology worldwide. Get in touch today to learn more.
Meet the Management Team
Igniting Hong Kong's Biotech Renaissance with Advanced Cryopreservation
President
Ken Lee
Ken Lee is the founder of Lucy Biotech and holds an MBA from the Richard Ivey School of Business. Ken has over 25 years of biotech industry experience, and is very seasoned in preclinical and clinical development of biologics. As President & CEO at iProgen Biotech, Ken managed all aspects of the business operations, including financing, implementation of business plans, communication towards stakeholders, recruiting and managing employees, and developing collaborations and partnerships.
Chief Executive Officer
Melodie Lu
Melodie Lu has been the CEO and a member of the Board of Directors for Lucy Biotech since November 2022. Prior to becoming a member of Lucy, Melodie amassed 7 years as the director of operations at iProgen Biotech Inc. Melodie began her career at the Jack Bell Research Centre at the University of British Columbia then, transitioned to work in a start-up biotech company. She leads a team of scientists and technicians in recombinant protein production.
VP of Business Development
Nigel McNabb
Nigel McNabb has close to 20 years of experience in corporate and business development. As a seasoned business development expert, Nigel has worked as a Business Transformation Consultant, Business Architect, as well as a Project Manager. His key areas of expertise include innovative business strategy, design and implementation. Nigel holds a B.Sc. in Biology from the University of British Columbia and an MBA from the Richard Ivey School of Business.
Senior Advisor
Vivien Webb
Vivien experienced more than 35 years in private wealth management in Asian, working across several top international institutions, including Morgan Stanley, Goldman Sachs, HSBC, and Chase Manhattan Bank. Throughout her career, Vivien enjoyed senior-level relationship management and advisory responsibilities, witnessing a tremendous increase in Asian-based entrepreneurs who not only built fast-growing successful businesses but also sought to use their success philanthropically.
Senior Advisor
Virginia Devereux Wong
Virginia’s career spans over 35 years in the mutual fund industry with a strong track record of business success and a renowned reputation in establishing new businesses. Virginia first became involved in the funds industry in 1987 and has since established her asset management business in private partnership, and subsequently, in working for global asset managers and major investment banks, such as SEI, Goldman Sachs, Standard Life Investments and HSBC Global Private Banking. She currently serves as a Senior Advisor and Board Member for AutoML Capital, an AI Powered Investment Management Company. She also serves as a Board member of Pathfinders Hong Kong (Non-Profit).
Greater China Development Lead
Dr. Yue Huang
Dr. Huang is a seasoned global R&D executive with 23+ years of pharmaceutical industry experience, with specialties in the clinical pharmacology and exploratory and late stage R&D. His career path includes Quintiles, Roche), Genentech, Novartis, more recently, Merck Serono R&D Hub as the Head of Global Development & Translational Medicine China, Simcere Pharma Group as R&D Executive Director. Dr. Huang has worked directly in numerous pharmaceutical and biotechnology pipeline encompassing small molecules, large biologics, and novel modalities including nucleic acid, cell and gene therapy, and spanning the entire project life-cycle from early discovery to commercial stage.